Angiotensin IV analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-05. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
[C(O)NH]3 ⇌ [C(O)NH]2[C(O)N]− + H+ (pKa = 6.88) [C(O)NH]2[C(O)N]− ⇌ [C(O)NH][C(O)N]22− + H+ (pKa = 11.40) [C(O)NH][C(O)N]22− ⇌ [C(O)N]33− + H+ (pKa = 13.5) Cyanuric acid is noted for its strong interaction with melamine, forming insoluble melamine cyanurate. This interaction locks the cyanuric acid into the tri-keto tautomer. Melamine cyanurate is cited as an example of supramolecular chemistry.
=== RNA sequencing === RNA sequencing was one of the earliest forms of nucleotide sequencing. The major landmark of RNA sequencing is the sequence of the first complete gene and the complete genome of Bacteriophage MS2, identified and published by Walter Fiers and his coworkers at the University of Ghent (Ghent, Belgium), in 1972 and 1976. Traditional RNA sequencing methods require the creation of a cDNA molecule which must be sequenced.
== Overview == Mutations can involve the duplication of large sections of DNA, usually through genetic recombination. These duplications are a major source of raw material for evolving new genes, with tens to hundreds of genes duplicated in animal genomes every million years. Most genes belong to larger gene families of shared ancestry, detectable by their sequence homology. Novel genes are produced by several methods, commonly through the duplication and mutation of an ancestral gene, or by recombining parts of different genes to form new combinations with new functions. Here, protein domains act as modules, each with a particular and independent function, that can be mixed together to produce genes encoding new proteins with novel properties. For example, the human eye uses four genes to make structures that sense light: three for cone cell or colour vision and one for rod cell or night vision; all four arose from a single ancestral gene. Another advantage of duplicating a gene (or even an entire genome) is that this increases engineering redundancy; this allows one gene in the pair to acquire a new function while the other copy performs the original function. Other types of mutation occasionally create new genes from previously noncoding DNA. Changes in chromosome number may involve even larger mutations, where segments of the DNA within chromosomes break and then rearrange. For example, in the Homininae, two chromosomes fused to produce human chromosome 2; this fusion did not occur in the lineage of the other apes, and they retain these separate chromosomes.
Sources: en.wikipedia.org
== Art == Although some historians dates the start of the trepang industry to 1720, Regina Ganter of Griffith University suggests that the start of the industry may be around 1640. Artistic evidence, like the Arnhem land rock, also suggests that contact may go as far back as the 1500s. The land rock depicts the extensive boat voyages that spanned thousands of miles around the Australian cost line. The north-west monsoon, which arrived each December, also dictated the semi-permanent locations where the Makassan people would settle. These images likely contribute to narrative stories, which are associated with the ancestral story telling tradition of the indigenous people of Arnhem Land. Artist Nandabitta Maminyamandja (1911 - 1981) of the Anindilyakwa people painted Macassan prau and trepang curing in 1974. This work is natural pigments on eucalyptus bark and is now on display in the National Gallery of Australia. The subject matter includes the communication that the trepanging industry fostered, most importantly early trade interactions. In 1883, the trepanging trade started to decline with the South Australian governments implementation of the trepanging license. Trepanging-related art work was consistent with the influx of missionaries into the area, as there was a greater demand for secular stories. The missionaries did not encourage the production of ceremonial stories, and they established clear regulations around the subject matter that was depicted and distributed.
MenAfriVac is a meningococcal vaccine developed for use in sub-Saharan Africa for children and adults between 9 months and 29 years of age against meningococcal bacterium Neisseria meningitidis group A. The vaccine costs less than US$0.50 per dose.
=== Observations of thin graphite layers and related structures === Transmission electron microscopy (TEM) images of thin graphite samples consisting of a few graphene layers were published by G. Ruess and F. Vogt in 1948. Eventually, single layers were also observed directly. Single layers of graphite were also observed by transmission electron microscopy within bulk materials, particularly inside soot obtained by chemical exfoliation. From 1961 to 1962, Hanns-Peter Boehm published a study of extremely thin flakes of graphite. The study measured flakes as small as ~0.4 nm, which is around 3 atomic layers of amorphous carbon. This was the best possible resolution for TEMs in the 1960s. However, it is impossible to distinguish between suspended monolayer and multilayer graphene by their TEM contrasts, and the only known method is to analyze the relative intensities of various diffraction spots. The first reliable TEM observations of monolayers are likely given in references 24 and 26 of Geim and Novoselov's 2007 review. In 1975, van Bommel et al. epitaxially grew a single layer of graphite on top of silicon carbide. Others grew single layers of carbon atoms on other materials. This "epitaxial graphene" consists of a single-atom-thick hexagonal lattice of sp2-bonded carbon atoms, as in free-standing graphene.
== Markers == Myoepithelial cells are true epithelial cells positive for keratins, not to be confused with myofibroblasts which are true mesenchymal cells positive for vimentin. These cells are generally positive for alpha smooth muscle actin (αSMA), cytokeratin 5/6 and other high molecular weight cytokeratins, p63 and caldesmon. Myoepithelial cells are stellate in shape and are also known as basket cells. They lie between the basement membrane and glandular epithelium. Each cell consists of a cell body from which 4-8 processes radiate and embrace the secretory unit. Myoepithelial cells have contractile functions. They help in expelling secretions from the lumen of secretory units and facilitate the movement of saliva in salivary ducts.
Sources: en.wikipedia.org
In a 2016 survey conducted by the Varkey Foundation and Populus, the question of whether or not those 15 to 21 favored legal migration received mixed responses. In the United States, that margin of support was 16%, higher than the global average of 8%. (See chart above.) According to Gallup, Americans aged 18 to 34 are more likely to view immigration as a "good thing" than their elders. By 2024, a clear majority of young adults supported increased patrols along the American-Mexican border to combat illegal immigration into the United States.
== Procedure == Sperm washing takes place in a laboratory following sperm donation. Sperm may be washed by density gradient centrifugation or by a "direct swim-up" technique that does not involve centrifugation. In normal semen samples, centrifugation causes no more DNA damage to spermatozoa than a direct swim-up technique. Washed sperm is concentrated in Ham's F-10 media without L-glutamine, warmed to 37 °C (99 °F). A chemical known as a cryoprotectant is added to the sperm to aid the freezing and thawing process. Further chemicals may be added which separate the most active sperm in the sample, as well as extend or dilute the sample so that vials for a number of inseminations are produced.
== Signal peptide as a therapeutic target == Signal peptide is a potential (therapeutic) antiviral target. The stable signal peptides (SSPs) of mammarenavirus viral glycoprotein precursors re-associate with mature spike proteins after their co-translational cleavage. SSPs with a penultimate N-terminus glycine are a target for NMT inhibitors, which inhibit the myristoylation of signal peptides and target the signal peptide for proteasomal degradation, affecting virus–cellular fusion.
== Management of intoxication == Management of PCP intoxication mostly consists of supportive care – controlling breathing, circulation, and body temperature – and, in the early stages, treating psychiatric symptoms. Benzodiazepines, such as lorazepam, are the drugs of choice to control agitation and seizures (when present). Typical antipsychotics such as phenothiazines and haloperidol have been used to control psychotic symptoms, but may produce many undesirable side effects – such as dystonia – and their use is therefore no longer preferred; phenothiazines are particularly risky, as they may lower the seizure threshold, worsen hyperthermia, and boost the anticholinergic effects of PCP. If an antipsychotic is given, intramuscular haloperidol has been recommended. Forced acid diuresis (with ammonium chloride or, more safely, ascorbic acid) may increase the clearance of PCP from the body, and was somewhat controversially recommended in the past as a decontamination measure. However, it is now known that only around 10% of a dose of PCP is removed by the kidneys, which would make increased urinary clearance of little consequence; furthermore, urinary acidification is dangerous, as it may induce acidosis and worsen rhabdomyolysis (muscle breakdown), a not-unusual manifestation of PCP toxicity.
Branched-chain amino acid aminotransferase (BCAT), also known as branched-chain amino acid transaminase, is an aminotransferase enzyme (EC 2.6.1.42) which acts upon branched-chain amino acids (BCAAs). It is encoded by the BCAT2 gene in humans. The BCAT enzyme catalyzes the conversion of BCAAs and α-ketoglutarate into branched chain α-keto acids and glutamate. The structure to the right of branched chain amino acid aminotransferase was found using X-ray diffraction with a resolution of 2.20 Å. The branched-chain amino acid aminotransferase found in this image was isolated from mycobacteria. This protein is made up of two identical polypeptide chains, totaling 372 residues. The biological function of branched-chain amino acid aminotransferases is to catalyse the synthesis or degradation of the branched chain amino acids leucine, isoleucine, and valine. In humans, branched chain amino acids are essential and are degraded by BCATs.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.